Abiopharma

🔍 Barry James Christopher (Director)

Company: LivaNova PLC (LIVN)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Acquired 4,042 shares of Ordinary Shares (Direct)
  Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 8,404.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 486 shares of Ordinary Shares at $79.7 per share (Direct)
  Date: 2026-06-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 7,918.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 4,042 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F4, F4
• Acquired 2,383 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,383.00 | transaction_form_type: 4 | Footnotes: F2, F5, F5

Footnotes:

• F1: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), 1.00 GBP par value.
• F2: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement.
• F3: Shares withheld to satisfy tax liability.
• F4: RSUs granted under the 2025 Plan on June 15, 2025 that vested on June 15, 2026.
• F5: The RSUs, granted under the 2025 Plan, vest on June 15, 2027, subject to continued service during the vesting period and the terms of the 2025 Plan award agreement.